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ABSTRACT 
Background:The most common cause of hyperthyroidism is Graves' disease. TRH and TSH are 
hormonal factors that modulate and control thyroid function in Graves' disease. In the immunological 
aspect, Graves' disease is played by the role of T-reg, IL-4, and anti-TPO. Graves' disease treatment goal 
is to inhibit thyroid hormone secretion by administering thionamide. The evaluationof this treatment is its 
hormonal and immunological aspects.Objective:To describe the effect of thionamide on serum TRH, 
TSH, IL-4, T-reg, and anti-TPO levels in Graves' disease. Methodology:This study is a clinical trial study 
in 25 study participants. All study participants were given thionamide, namely PTU 300 mg for three 
months and blood samples were taken for laboratory tests. Serum TRH, TSH, IL-4, and anti-TPO levels 
were examined by ELISA. The T-reg FOXP3 gene polymorphism was examined by PCR.Results:The 
mean levels at the beginning and after three months of therapy are:serum TRH 92.589 pg/ml and 115.944 
pg/ml; serum TSH 0.041 mU/l and 0.223 mU/l; serum IL-4 19.759 pg/ml and 23.040 pg/ml; T-reg 
FOXP3 gene polymorphism 0.621 ng/ml and 0.518 ng/ml; serum anti-TPO 2697.539 pg/ml and 2604710 
pg/ml. Increased levels of serum TRH and TSH levels were statistically significant. The change in serum 
IL-4, T-reg FOXP3 gene polymorphism, and anti-TPO levelswere not statistically 
significant.Conclusion:The administration of thionamide in Graves' disease for three months will 
significantly increase serum TRH and TSH levels and not have a significant effect on serum IL-4, T-reg 
FOXP3 gene polymorphism, and anti-TPO levels. 
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INTRODUCTION 
The most common cause of hyperthyroidism in the world is Graves' disease. Graves' disease 
occurs in 2 - 2.5% of women and 0.2 - 0.6% of men. The factors that play a role in Graves' disease are 
environment, genetic disorders, and autoimmune processes. Thyroid-stimulating hormone (TSH) is one of 
the links in a complex signaling network that modulates and controls thyroid growth and function in 
Graves' disease. TSH not only works at glands and thyroid function. TSH circulating in the tissues is 
controlled by thyrotropin-releasing hormone (TRH) levels and the feedback effect of thyroid hormone 
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levels on the tissues. In the immunological aspect of Graves' disease, at higher level, is controlled by 
T-regulator (T-reg) cells. In the next stage, the T-reg will differentiate T-helper (Th) cells which is will 
produce various inflammatory cytokines, including interleukin-4 (IL-4). In addition to T-reg cells, B cells 
have role in humoralto produce several antibodies, one of them is anti-TPO[1],[2],[3]. 
The stages of biosynthetic processes and secretions of thyroid hormones are stimulated by TSH. 
Thyroid hormone levels are controlled by TSH, which is produced by the anterior pituitary gland. TSH 
levels are regulated by TRH produced by the hypothalamus gland. Then, Thyroid hormones will provide 
negative feedbacks to pituitary gland and hypothalamus [4]. 
Graves' disease is not only explained by the theories of comparison Th1 and Th2. Lately 
attention has been paid to T-reg cells. Initially T-reg cells are described as CD4 + suppressor cells. Later, 
regulatory T cells (T-reg) are known as subtypes of CD4 which has specificities in the presence of CD25 
expression, where the expression of the Forkhead box P3 (FOXP3) molecule is a special marker from 
T-reg. CD4 + CD25 + Foxp3 + Natural T-reg is considered as the main component of T-reg cells and 
emerges from the thymus as fully differentiated cells. And the abnormality of the T-reg number and its 
function has an effect on several autoimmune diseases[3],[5]. 
Interleukin-4 is the main cytokine that associated with autoimmune thyroid disease. IL-4 plays a 
main role in the process of differentiating naïve T cells into Th cells and increasing the expression of 
MCH class II in B cells, dendritic cells and macrophage cells. IL-4 stimulates the isotype of 
Immunoglobulin G3 (IgG3-SCS) secreting cell which is associated with the severity of Graves' disease. 
The increase in cytokine values in Graves' patients illustrate the activity and interplay of Th1 and Th2 
which are compatible with long-term inflammation and the damage process of the thyroid gland [6]. 
Anti-thyroid peroxidase antibodies (anti-TPO) are antibodies that bind to transmembrane 
proteins in tyrosite which are involved in the synthesis of thyroid hormones. Anti-TPO is also known as 
an microsomal anti-thyroid antibodies which is an important examination in autoimmune thyroid disease 
because it is found to be positive in more than 80% of patients with Graves' disease [4]. 
In general, the goal of treating hyperthyroidism in Graves' disease is to inhibit thyroid hormone 
secretion. In the treatment of Graves' disease, the levels of thyroid hormone and TSH are evaluated. 
Meanwhile, TRH levels have not been evaluated. The effect of therapy on Graves' disease should also 
influence the factors that play a role in immunological aspects, such as T-reg, IL-4, and anti-TPO. In this 
study, we want to see the effect of thionamide on levels of TRH, TSH, IL-4, T-reg, and anti-TPO in 
Graves' disease [4],[5],[6]. 
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METHODOLOGY 
Materials 
This study is a clinical trial study with pre and post treatment to the study sample. This study 
involved 25 patients with Graves' disease who had not received prior treatment and who controlled to the 
metabolic endocrine clinic at the RSUP Dr. M. Djamil Padang who has signed the informed consent. 
Pregnant patients, allergic to thionamide, and Graves’ relapse were excluded. All study participants were 
given initial therapy for three months of thionamide antithyroid treatment, PTU 300 mg. All blood 
samples have taken from this study participants for laboratory tests at the beginning and at the end of 
initial therapy. We examined variables like serum TRH, serum TSH, serum IL-4, T-reg FOXP3 gene 
polymorphism, and serum anti-TPO. This research has received an ethical approval from the Ethics 
Committee of Medical Faculty of Andalas University. 
Methods 
TRH serum, TSH serum, IL-4 serum, and anti-TPO serum were examined with enzyme-linked 
immunosorbent assay techniques (ELISA). The FOXP3 T-reg gene polymorphism was examined using 
the polymerase chain reaction (PCR) method. 
Statistical analysis was carried out by comparing TRH serum levels, TSH serum, IL-4 serum, 
T-reg FOXP3 gene polymorphism, and anti-TPO serum at the beginning and at the end of three months 
therapy of thioanamide. Paired t-test was used to analyze the differences of before and after the three 
months therapy. A value of p <0.05 was considered as significant. 
RESULT AND DISCUSSION 
The baseline characteristics of this study are shown in table 1. From the study, the range of 
patients’ age are from 17 to 33 years, with the average of age is 27.48 (5.6) years. The number of female 
patients in this study is more than male patients, with percentage of women are 96% and men are 4%. In 
this study, only one from the men patients was attended at the study. The average of age from this study’s 
sample is smaller than some other studies. The average of age was obtained in this study is appropriate 
with The Indonesian Society of Endocrinology Task Force on Thyroid Diseases (2012) which states that 
Graves' disease appears more frequently at the third and fourth of decades [7],[8]. 
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Table 1. Baseline Characteristics 
Characteristics (n=25) Mean (SD) Median n (%) 
Average Age (yo) 27,48 (5,6)   
Sex 
Male 
Female 
   
1 (4%) 
24 (96%) 
Wayne Index 23,44 (1,4)   
FT4 (pmol/l) 55,55 (17,98)   
TRH (mU/l)  92,589  
TSH (pg/ml) 
T-reg FOXP3gene polymorphism (ng/ml) 
IL-4 (pg/ml) 
Anti-TPO (pg/ml) 
 
0,621 (0,23) 
19,759 (7,03) 
2697,539 (479,72) 
0,041 
 
 
 
The higher percentage of womenthan men was also found by Voskuhl (2011). Voskuhl (2011) 
states that women are more prone to suffer from autoimmune disorders. This is in accordance with Ngo et 
al (2014) which states that autoimmune disorders are more common in women. There are several studies 
that gave the prevalence of autoimmune disorders in several countries. Carle et al (2011), Gaujoux et al 
(2006), Guo et al (2013), and Phitayakorn et al (2013) reported that Graves' disease was more prevalent 
among women in the United States, France, Denmark, and China. The Indonesian Society of 
Endocrinology Task Force on Thyroid Diseases (2012) states that the ratio of women to men with Graves' 
disease is 8: 1 [7],[8],[9]. 
 
Table 2. Changes in TRH and TSH serum levels at initial and after three months of thionamidetherapy 
Variable Median p 
Initial (n=25) After three months (n=25) 
TRHSerum(pg/ml) 92,589 115,944 0,001 
TSHSerum(mU/l) 0,041 0,223 0,001 
 
Changes in TRH and TSH serum levels at initial and after three months of thionamide therapy 
can be seen in table 2. Median of TSH serum level before administration of thionamide in this study was 
0.041 mU/l. After giving thionamide for three months, the median of TSH serum level was 0.223 mU/l. 
There was an increase in TSH serum level after administration of thionamide for three months, 
statistically significant. This result is supported by Schimdt and Braunbeck (2011) who stated that 
zebrafish who get thionamide will experience thyroid gland hyperplasia and increased blood vessel flow 
in the Thyroid gland tissue. Immunohistological staining at cells which are producing TSH in the pituitary 
shows a significant increase. This indicates that an increase occurs in TSH serum levels of zebrafish after 
the administration of thionamide [10]. 
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Median serum TRH level before administration of thionamide in this study was 92.589 pg/ml. 
After giving thionamide for three months, the median serum TRH level was 115.944 pg/ml. There was an 
increase in TRH levels after the administration of thionamide for three months, which is statistically 
significant. Propylthiouracil is effective in reducing thyroid hormone levels back to normal with the initial 
therapy for three months. This decrease in thyroid hormone levels will be followed not only by increased 
in TSH levels, but also by an increase in TRH levels through the hypothalamic-pituitary-thyroid axis. 
Alkemade (2015) and Guissouma et al (2002).[11],[12]. 
 
Tabel 3. Changes in T-reg FOXP3 polymorphism serum, IL4 serum and anti-TPO serum levels at initial 
and after three months of thionamide therapy 
Variable Mean p 
Initial (n=25) After three months (n=25) 
T-reg FOXP3 gene 
polymorphism (ng/ml) 
0,621 (0,23) 0,518 (0,25) 0,124 
IL-4 (pg/ml) 19,759 (7,03) 23,040 (7,35) 0,150 
Anti-TPO (pg/ml) 2697,539 (479,72) 2604,710 (458,80) 0,361 
 
Changes in T-reg FOXP3 polymorphism serum, IL4 serum and anti-TPO serum levels at initial 
and after three months of thionamide therapycan be seen in table 3. The mean T-reg FOXP3 
polymorphism before administration of thionamide in this study was 0.621 ng/ml. After giving 
thionamide for three months, the average T-reg FOXP3 polymorphism in this study was 0.518 ng/ml. The 
change in FOXP3 T-reg polymorphism statistically was not significant. 
The mean serum IL-4 level before administration of thionamide in this study was 19.759 pg/ml. 
After giving thionamide for three months, the mean serum IL-4 level in this study was 23,040 pg/ml. This 
change in IL-4 levels statistically was not significant. 
The mean serum anti-TPO level before administration of thionamide in this study was 2,697,539 
pg/ml. After giving thionamide for three months, the mean serum anti-TPO level in this study was 
2,604,710 pg/ml. This change in the level of anti-TPO statistically was not significant. 
Humar et al (2008) explained that thionamide is an antithyroid drug with immunomodulating 
effects. This was proven in his research that showed thionamide which inhibited the synthesis of 
proinflammatory cytokines TNF- and interferon-. Decroli et al (2014) found that administration of 
thionamide for one year would reduce IL-4 levels. Levels of IL-4 were found to drop dramatically in the 
first six months of thionamide therapy. However, the influences of thionamide on T-reg and anti-TPO has 
not been widely discussed [6], [13]. 
This study shows that the administration of initial therapy of thionamide for three months will 
improve Graves' disease hormonally, which are normal levels of FT4, significantly increased TSH and 
TRH serum levels. In this study, there were no significant changes in the FOXP3 T-reg gene 
polymorphism, IL-4 levels, and anti-TPO serum. It explains that the importance to continue the 
administration of thionamide in Graves' disease to see its immunological effects [3],[6],[14]. 
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CONCLUSION 
The administration of thionamide in Graves' disease for three months will significantly increase 
TRH and TSH serum levels and doesn’t have a significant effect on the T-regFOXP3 gene polymorphism, 
IL-4 serum levels, and anti-TPO serum. 
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